Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study
- PMID: 28687376
- DOI: 10.1016/S1470-2045(17)30445-X
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study
Erratum in
-
Correction to Lancet Oncol 2017; 18: 1022-39.Lancet Oncol. 2017 Aug;18(8):e433. doi: 10.1016/S1470-2045(17)30531-4. Epub 2017 Jul 26. Lancet Oncol. 2017. PMID: 28759380 No abstract available.
Abstract
Background: Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries.
Methods: We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000-07 and the corresponding time trends during 1995-2007. Incidence was calculated as the number of new cases divided by the corresponding total person-years in the population. 5-year relative survival was calculated by the Ederer-2 method. Seven registries (Belgium, Bulgaria, Finland, Ireland, the Netherlands, Slovenia, and the Navarra region in Spain) provided additional data for hospitals treating about 220 000 cases diagnosed in 2000-07. We also calculated hospital volume admission as the number of treatments provided by each hospital rare cancer group sharing the same referral pattern.
Findings: Rare cancers accounted for 24% of all cancers diagnosed in the EU during 2000-07. The overall incidence rose annually by 0.5% (99·8% CI 0·3-0·8). 5-year relative survival for all rare cancers was 48·5% (95% CI 48·4 to 48·6), compared with 63·4% (95% CI 63·3 to 63·4) for all common cancers. 5-year relative survival increased (overall 2·9%, 95% CI 2·7 to 3·2), from 1999-2001 to 2007-09, and for most rare cancers, with the largest increases for haematological tumours and sarcomas. The amount of centralisation of rare cancer treatment varied widely between cancers and between countries. The Netherlands and Slovenia had the highest treatment volumes.
Interpretation: Our study benefits from the largest pool of population-based registries to estimate incidence and survival of about 200 rare cancers. Incidence trends can be explained by changes in known risk factors, improved diagnosis, and registration problems. Survival could be improved by early diagnosis, new treatments, and improved case management. The centralisation of treatment could be improved in the seven European countries we studied.
Funding: The European Commission (Chafea).
Copyright © 2017 Elsevier Ltd. All rights reserved.
Comment in
-
All tumours are rare, but some are rarer than others.Lancet Oncol. 2017 Aug;18(8):983-985. doi: 10.1016/S1470-2045(17)30466-7. Epub 2017 Jul 4. Lancet Oncol. 2017. PMID: 28687378 No abstract available.
Similar articles
-
The European study on centralisation of childhood cancer treatment.Eur J Cancer. 2019 Jul;115:120-127. doi: 10.1016/j.ejca.2019.04.024. Epub 2019 May 24. Eur J Cancer. 2019. PMID: 31132742
-
Epidemiology of rare cancers and inequalities in oncologic outcomes.Eur J Surg Oncol. 2019 Jan;45(1):3-11. doi: 10.1016/j.ejso.2017.08.018. Epub 2017 Sep 19. Eur J Surg Oncol. 2019. PMID: 29032924
-
Improving treatment results with reference centres for rare cancers: where do we stand?Eur J Cancer. 2017 May;77:90-98. doi: 10.1016/j.ejca.2017.02.006. Epub 2017 Apr 3. Eur J Cancer. 2017. PMID: 28384534 Review.
-
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035. Epidemiol Prev. 2016. PMID: 26951748
-
The burden of rare cancers in Europe.Adv Exp Med Biol. 2010;686:285-303. doi: 10.1007/978-90-481-9485-8_17. Adv Exp Med Biol. 2010. PMID: 20824452 Review.
Cited by
-
Laparoscopy-assisted trans gastric wedge resection: A safe treatment for gastric pyloric liposarcoma: A case report and literature review.Heliyon. 2024 Apr 27;10(9):e30410. doi: 10.1016/j.heliyon.2024.e30410. eCollection 2024 May 15. Heliyon. 2024. PMID: 38774071 Free PMC article.
-
Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.Cancers (Basel). 2024 Apr 12;16(8):1489. doi: 10.3390/cancers16081489. Cancers (Basel). 2024. PMID: 38672571 Free PMC article.
-
Amputation surgery associated with shortened survival in patients with localized extremity bone sarcoma.J Orthop. 2024 Mar 18;54:124-130. doi: 10.1016/j.jor.2024.03.017. eCollection 2024 Aug. J Orthop. 2024. PMID: 38560589
-
Evidence-Based Recommendations in Primary Tracheoesophageal Puncture for Voice Prosthesis Rehabilitation.Healthcare (Basel). 2024 Mar 14;12(6):652. doi: 10.3390/healthcare12060652. Healthcare (Basel). 2024. PMID: 38540616 Free PMC article. Review.
-
Current prospects of hereditary adrenal tumors: towards better clinical management.Hered Cancer Clin Pract. 2024 Mar 26;22(1):4. doi: 10.1186/s13053-024-00276-6. Hered Cancer Clin Pract. 2024. PMID: 38532453 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical